PetVivo Holdings, Inc. reported its fiscal second quarter 2025 results, with revenues decreasing 3% to $201,000 compared to the same period last year. This was partially offset by a 24% increase in sales to distributors as the company expanded its nationwide network. Gross profit for the quarter totaled $180,000, representing 89.5% of revenues.
The company implemented a strategic cost reduction and restructuring program, leading to a 25% decrease in operating expenses to $2.4 million. General and administrative expenses decreased by $425,000, and sales and marketing expenses decreased by $458,000, contributing to an improved net loss of $2.2 million, or $(0.11) per share.
PetVivo reiterated its full fiscal year 2025 net revenue outlook of approximately $1.5 million, projecting a 50% growth over the prior year. The company also announced the appointment of Mike Eldred to its board and initiated a canine elbow study with Orthobiologic Innovations to support its distribution strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.